Inhibition by diazepam of the tremor and the increase of cerebellar cGMD content elicited by harmaline.
D000470:Alkaloids / Q000037:antagonists & inhibitors*; D000818:Animals; D001665:Binding Sites; D002531:Cerebellum / Q000187:drug effects* / Q000378:metabolism; D006152:Cyclic GMP / Q000378:metabolism*; D003975:Diazepam / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D007211:Indoles / Q000037:antagonists & inhibitors*; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000037:antagonists & inhibitors*; D010095:Oxotremorine / Q000037:antagonists & inhibitors; D011689:Purkinje Cells / Q000187:drug effects; D011725:Pyridines / Q000037:antagonists & inhibitors; D051381:Rats; D014202:Tremor / Q000139:chemically induced / Q000517:prevention & control*
D000470:Alkaloids; D007211:Indoles; D008996:Monoamine Oxidase Inhibitors; D011725:Pyridines; D010095:Oxotremorine; D006152:Cyclic GMP; D003975:Diazepam